Immunotherapy has revolutionized cancer treatment in the clinic, but without benefiting every patient.
This could lead to new approaches to treat cancer patients resistant to checkpoint blockade immunotherapy.
candidate at the UMSOM Center for Immunology and Carcinogenesis Research and lead author of the study.
